Premium
Tamoxifen decreases human prostate CPK concentration
Author(s) -
Geller Jack,
Albert Jerry D.,
Kirshner Miriam,
Liu Junda
Publication year - 1985
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990070305
Subject(s) - prostate , tamoxifen , stroma , medicine , estrogen , endocrinology , prostate cancer , creatine kinase , urology , epithelium , megestrol acetate , cancer , pathology , immunohistochemistry , breast cancer
Creatine phosphokinase (CPK) was measured in whole prostate tissue of patients with benign prostatic hypertrophy (BPH) who were given Tamoxifen and/or megestrol acetate for seven days prior to transurethral resection of the prostate. Tamoxifen and Tamoxifen plus Megace®, but not Megace® alone, significantly decreased CPK concentrations in whole prostate tissue in comparison to untreated controls, suggesting that CPK is an estrogen‐dependent enzyme in the prostate. CPK concentration was also measured separately in mechanically separated prostate stroma and epithelium. The levels of CPK were 2.19 times higher in stroma than epithelium. This study suggests that CPK may be a marker for estrogen stimulation of the stroma in BPH tissue.